Previous Close | 4.25 |
Open | 4.31 |
Bid | 4.91 x 47300 |
Ask | 5.10 x 43500 |
Day's Range | 4.25 - 4.31 |
52 Week Range | 3.63 - 5.10 |
Volume | |
Avg. Volume | 674 |
Market Cap | 2.177B |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | 31.88 |
EPS (TTM) | 0.16 |
Earnings Date | Feb 05, 2025 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Mar 13, 2020 |
1y Target Est | N/A |
Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the Centers for Medicare & Medicaid Services has finalized a proposal that will expand patients access to high activity K3 knees in the United States. The proposal enables a large patient group of active K21 functional level amputees to gain access to bionic knee technology. Previously, Medicare had restricted access to these knees to only high-active amputees classified as
Össur, a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®, announced today that the company`s emissions reduction targets have been validated by the Science Based Targets initiative (SBTi).